Blood biomarkers of osteoporosis in mild cognitive impairment and Alzheimer's disease

Journal of Neural Transmission

Volumn 116, Issue 7, 2009, Pages 905-911

  Luckhaus, Christian ^a   Mahabadi, Bijan ^a   Grass Kapanke, Brigitte ^b   Jänner, Michaela ^a   Willenberg, Holger ^a   Jäger, Marcus ^a   Supprian, Tillmann ^a   Fehsel, Karin ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Krankenhaus Maria Hilf   (Germany)

Author keywords

Alzheimer's disease; Biomarkers; Comorbidity; Mild cognitive impairment; Osteoporosis

Indexed keywords

BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; OSTEOPROTEGERIN; VITAMIN D;

AGED; ALZHEIMER DISEASE; ARTICLE; BIOSYNTHESIS; BLOOD SAMPLING; BONE REMODELING; CATABOLISM; CLINICAL ARTICLE; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; OSTEOPOROSIS; PLASMA; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BONE AND BONES; BONE REMODELING; COGNITION DISORDERS; COLLAGEN; COMORBIDITY; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS; OSTEOPROTEGERIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 67651180550     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-009-0241-x     Document Type: Article

References (44)

1. G Cantarella D Uberti T Carsana 2003 Neutralization of TRAIL death pathway protects human neuronal cell line from beta-amyloid toxicity Cell Death Differ 10 134 141
2. H Carlsten 2005 Immune responses and bone loss: the estrogen connection Immunol Rev 208 194 206
3. S Christgau O Bitsch-Jensen HN Bjarnason EG Henriksen P Qvist P Alexandersen DB Henriksen 2000 Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy Bone 26 505 511
4. F Corallini E Rimondi P Secchiero 2008 TRAIL and osteoprotegerin: a role in endothelial physiopathology Front Biosci 13 135 147 (Pubitemid 351594767)
5. E Emanuele E Peros GA Scioli 2004 Plasma osteoprotegerin as a biochemical marker for vascular dementia and Alzheimer's disease Int J Mol Med 13 849 853
6. MF Folstein SE Folstein PR McHugh 1975 Mini-mental-state Psychiatry Res 12 189 198
7. C Franceschi M Bonafe S Valensin 2000 Inflammaging. An evolutionary perspective on immunosenescence Ann N Y Acad Sci 908 244 254
8. Härting C, Markowitsch HJ, Neufeld H et al (eds) (2000) WMS-R Wechsler Gedächtnistest-revidierte Fassung. Deutsche Adaption der Wechsler Memory Scale. Verlag Hans Huber, Bern
9. I Hindmarch H Lehfeld P Jongh 1998 The Bayer Activities of Daily Living Scale (B-ADL) Dement Geriatr Cogn Disord 9 Suppl 2 20 26
10. LC Hofbauer M Schoppet 2007 Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases JAMA 292 490 495
11. LC Hofbauer S Cepok B Hemmer 2004 Osteoprotegerin is highly expressed in the spinal cord and cerebrospinal fluid Acta Neuropathol 107 575 577
12. Ihl R, Frölich L (1991) Die Reisberg-Skalen. Beltz Verlag, Weinheim
13. Ihl R, Grass-Kapanke B (2000) Manual-Test zur Früherkennung von Demenzen mit Depressionsabgrenzung. Libri Books on Demand, Hamburg
14. C Johansson I Skoog 1996 A population-based study on the association between dementia and hip fractures in 85-year olds Aging (Milano) 8 189 196
15. S Jono Y Ikari A Shioi 2002 Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease Circulation 106 1192 1194
16. A Jorm 1994 A short form of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): development and cross-validation Psychol Med 24 145 153
17. KG Kahl W Greggersen S Rudolf 2006 Bone mineral density, bone turnover, and osteoprotegerin in depressed women with and without borderline personality disorder Psychosomat Med 68 669 674
18. V Kartsogiannis H Zhou NJ Horwood 1999 Localisation of RANKL (receptor activator of NFkB ligand) mRNA and protein in skeletal and extraskeletal tissues Bone 25 525 534
19. A Kertesz N Nadkarni W Davidson 2000 The Frontal Behavioral Inventory in the differential diagnosis of frontotemporal dementia J Int Neuropsychol Soc 6 460 468
20. S Kiechl P Werner M Knoflach 2006 The osteprotegerin/RANK/RANKL system: a bone key to vascular disease Expert Rev Cardiovasc Ther 4 801 811
21. E Kipen RD Helme JD Wark 1995 Bone density, vitamin D nutrition, and parathyroid hormone levels in women with dementia J Am Geriatr Soc 43 1088 1091
22. S Kudlacek B Schneider W Woloszczuk 2003 Serum levels of osteoprotegerin increase with age in a healthy adult population Bone 32 681 686
23. ES Leib M Lewiecki N Binkley RC Hamdy 2004 Official positions of the international society for clinical densiometry J Clin Densiometry 7 1 6
24. LY Lui K Stone JA Cauley 2003 Bone loss predicts subsequent cognitive decline in older women: the study of osteoporotic fractures J Am Geriatr Soc 51 38 43
25. A Martin-Villaba I Herr I Jeremias 1999 CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons J Neurosci 19 3809 3817
26. MJ McKenna R Freaney 1998 Secondary hyperparathyroidism in the elderly; means to defining hypovitaminosis D Osteoporos Int 8 Suppl S3 S6
27. G McKhann D Drachman M Folstein 1984 Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease Neurology 34 939 944
28. JC Morris 1997 The Clinical Dementia Rating (CDR): current version and scoring rules Neurology 43 2412 2414
29. U Naumann W Wick R Beschorner 2004 Expression and functional activity of osteoprotegerin in human malignant gliomas Acta Neuropathol 107 17 22
30. L Ovesen R Andersen J Jakobsen 2003 Geographical differences in vitamin D status, with particular reference to European countries Proc Nutr Soc 62 813 821
31. RC Petersen GE Smith SC Waring 1999 Mild cognitive impairment. Clinical characterization and outcome Arch Neurol 56 303 308
32. D Rachon J Mysliwska K Suchecka-Rachon 2002 Effects of oestrogen deprivation on interleukin-6 production by blood mononuclear cells of postmenopausal women J Endocrinol 172 387 395
33. Reitan RM (1979) Trail Making Test (TMT). Hogrefe Verlag, Bern
34. Y Sato T Asoh K Oizumi 1998 High prevalence of vitamin D deficiency and reduced bone mass in elderly women with Alzheimer's disease Bone 23 555 557
35. M Schoppet KT Preissner LC Hofbauer 2002 RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function Arterioscler Thromb Vasc Biol 22 549 553
36. KI Shulman 2000 Clock-drawing: is it the ideal cognitive screening test? Int J Geriatr Psychiatry 15 548 561
37. WS Simonet DL Lacey CR Dunstan 1997 Osteoprotegerin: a novel secreted protein involved in the regulation of bone density Cell 89 309 319
38. ZS Tan S Seshadri A Beiser 2005 Bone mineral density and the risk of Alzheimer disease Arch Neurol 62 107 111
39. Thalmann B, Monsch AU, Bernasconi F et al (1998) Die CERAD Neuropsychologische Testbatterie-Ein gemeinsames minimales Instrumentarium zur Demenzabklärung. Memory Clinic, Geriatrische Universitätsklinik, Basel
40. D Uberti G Cantarella F Facchetti 2004 TRAIL is expressed in the brain cells of Alzheimer's disease patients Neuroreport 15 579 581
41. K Yaffe W Browner J Cauley 1999 Association between bone mineral density and cognitive decline in older women J Am Geriatr Soc 47 1176 1182 (Pubitemid 29473288)
42. K Yano E Tsuda N Washida 1999 Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis J Bone Miner Res 14 518 527
43. H Yasuda N Shima N Nakagawa 1998 Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro Endocrinology 139 1329 1337
44. Y Zhang S Seshadri RC Ellison 2001 Bone mineral density and verbal memory impairment: third National Health and Nutrition Examination Survey Am J Epidemiol 154 795 802